W
WAVEMAN · COMPANY
XLO · Xilio Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

XLO

Xilio Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001840233
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$43.9K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
13
13F, latest reported quarter
REVENUE GROWTH
+589.9%
XBRL, annual
NET MARGIN
-80.1%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$43.9K over 180 days
more than 72% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
13 funds added or opened last quarter
below 78% of Pharma & Biotech
REVENUE
+589.9% year over year
more than 94% of Pharma & Biotech
MARGIN
-80.1% net margin
below 62% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -10.4%
-10.4%12M
-28%-11%+6%+22%2025-092025-102025-122026-032026-052026-072026-09 2026-03-26 · Shannon James Samuel bought $43.9K2026-01-02 · Frankenfield Christopher James sold $4.5K2026-01-02 · Brennan Kevin M. sold $1.2K
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $43.9K bought by insiders over 180 days, 13 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Xilio Therapeutics, Inc. insiders bought a net $43.9K of stock across 26 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Shannon James Samuel
Director
BUY
2026-03-26
5,000.0
$43.9K
Brennan Kevin M.
SVP, FINANCE AND ACCOUNTING
SELL
2026-01-02
1,826.0
$1.2K
Frankenfield Christopher James
Chief Financial Officer
SELL
2026-01-02
7,030.0
$4.5K
Shannon James Samuel
Director
BUY
2025-06-17
25,000.0
$17.2K
Shannon James Samuel
Director
BUY
2025-06-16
45,000.0
$31.0K
26 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 21 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Bain Capital Life Sciences Investors, LLC
664,021.0 sh
$6.4M
GILEAD SCIENCES, INC.
650,389.0 sh
$6.2M
ORBIMED ADVISORS LLC
592,300.0 sh
$5.7M
Stonepine Capital Management, LLC
451,988.0 sh
$4.3M
Frazier Life Sciences Management, L.P.
422,505.0 sh
$4.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
VANGUARD EXTENDED MARKET INDEX FUND
$495.4K POSITION · AS OF 2026-03-31
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$109.8K POSITION · AS OF 2026-03-31
0.0%
Fidelity Extended Market Index Fund
$75.0K POSITION · AS OF 2026-02-28
0.0%
Fidelity Nasdaq Composite Index Fund
$7.6K POSITION · AS OF 2026-02-28
0.0%
Fidelity Total Market Index Fund
$33.4K POSITION · AS OF 2026-02-28
0.0%
Fidelity Series Total Market Index Fund
$26.2K POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$43.8M$6.3M
OPERATING INCOME$-42.0M$-60.6M$-79.1M$-89.1M
NET INCOME$-35.0M$-58.2M$-76.4M$-88.2M
EPS (DILUTED)-4.19-15.24-2.78-3.22
OPERATING CASH FLOW$-5.0M$-18.4M$-68.6M$-75.7M
CASH$137.5M$55.3M$44.7M$120.4M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →